Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Canaccord Genuity39th Annual Growth Conference in Bostonon August 7, 2019at 2:30 p.m. ET/ 11:30 a.m. PT; and
Wedbush Healthcare Conferencein New Yorkon August 13, 2019at 12:45 p.m. ET/ 9:45 a.m. PT.
A live audio webcast and replay of each presentation will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Chief Financial Officer
Source: Harpoon Therapeutics